CN113493417A - Temozolomide intermediate compound VII - Google Patents

Temozolomide intermediate compound VII Download PDF

Info

Publication number
CN113493417A
CN113493417A CN202010205396.9A CN202010205396A CN113493417A CN 113493417 A CN113493417 A CN 113493417A CN 202010205396 A CN202010205396 A CN 202010205396A CN 113493417 A CN113493417 A CN 113493417A
Authority
CN
China
Prior art keywords
compound
reaction
temozolomide
stirring
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010205396.9A
Other languages
Chinese (zh)
Other versions
CN113493417B (en
Inventor
时江华
闫路林
刘忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Priority to CN202010205396.9A priority Critical patent/CN113493417B/en
Publication of CN113493417A publication Critical patent/CN113493417A/en
Application granted granted Critical
Publication of CN113493417B publication Critical patent/CN113493417B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a temozolomide intermediate compound VII, which is a new intermediate VII obtained by performing one-step hydrolysis on an imidazole azo intermediate compound serving as a raw material and performing nucleophilic substitution on the hydrolyzed intermediate compound and p-nitrophenyl chloroformate.

Description

Temozolomide intermediate compound VII
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a temozolomide intermediate compound VII.
Background
Temozolomide (Temozolomide), chemical name 8-carbamoyl-3-methylimidazole [5,1-d]-1,2,3, 5-tetrazin-4 (3H) -one of formula: c6H6N6O2(ii) a Molecular weight: 194.15, respectively; CAS registry number 85622-93-1, structural formula as follows:
Figure BDA0002420633450000011
temozolomide was first developed by the university of aston, uk, and later by the german pioneer pauya pharmaceutical, and was marketed in the united states in 1999. Pharmacological research proves that temozolomide is a novel medicine with better curative effect on brain glioma; has high bioavailability, can be orally taken, is easy to permeate blood brain barrier, has no superimposed toxicity compared with other medicines, and has wider anti-tumor spectrum. Currently, temozolomide is a better anticancer drug for treating brain glioma and malignant melanoma, and the capsule of temozolomide is approved in Europe and America to be used for treating malignant glioma.
The conventional synthesis method of temozolomide is to take 5-amino-1H-imidazole-4-formamide or hydrochloride thereof as a raw material to react with sodium nitrite, diazotize the raw material and then react with methyl isocyanate to prepare temozolomide (Journal of the Chemical Society, Perkin Transactions l, 1998, 10: l669-1775), 5-aminoimidazole-4-formamide reacts with excessive sodium nitrite under the conditions of low temperature and acidity to obtain 5-diazoimidazole-4-formamide 2, the compound 2 reacts with methyl isocyanate in a mixed solution of dimethyl sulfoxide and ethyl acetate for 2 days at normal temperature, and the temozolomide product with high purity and high yield is obtained through a bipolar intermediate 3.
Figure BDA0002420633450000012
Although the reaction has high atom utilization rate and high yield, the methyl isocyanate has high toxicity, the reaction conditions are difficult to control and transport, and certain difficulty is brought to production.
To avoid the use of isocyanates (Journal of the Chemical Society, Perkin Transactions 1, 2002, 16: 1877) -1880) the literature reports the formation of 5-nitroimidazole 4-acetonitrile by the reaction of 5-nitroimidazole with potassium cyanate in the presence of nitric acid, followed by a multi-step reaction to temozolomide. The method has high yield, avoids methyl isocyanate with high toxicity and unstable diazo compound 5-diazoimidazole-4-formamide, but has long synthetic route which is too complex and is not suitable for industrial production.
Figure BDA0002420633450000021
Chinese patent application CN103626772 reports that 5-aminoimidazole-4-formamide is used as a raw material, a compound 5 is synthesized through two-step reaction, and then temozolomide is generated through cyclization by an oxidation cyclization reagent, and the route is as follows:
Figure BDA0002420633450000022
although this process is short in steps and does not use 5-diazoimidazole-4-carboxamide with methyl isocyanate, the oxidative ring reagent is I2、ICl、ICl3And H5IO6The toxic dangerous reagent containing iodine is high, but the final yield is only 49.8%.
In conclusion, the temozolomide preparation methods have the problems of long route, low yield and low purity; the use of a highly toxic methyl isocyanate chemical reagent is required; therefore, the problem to be solved at present is to explore a process route for temozolomide, which is simple and convenient to operate, short in production period, high in yield and more suitable for industrial production.
Disclosure of Invention
In order to solve the problems of long route, unstable intermediate, need of chemical reagents with high toxicity and the like in the preparation process of temozolomide in the prior art, the invention provides a novel temozolomide intermediate compound and a novel method for preparing temozolomide by using the compound; the method has the advantages of short reaction route, simple and convenient operation, milder reaction, economy, environmental protection and high yield, and is suitable for industrial production.
The invention is realized by the following technical scheme:
a temozolomide intermediate compound represented by formula VII:
Figure BDA0002420633450000031
a preparation method of a temozolomide intermediate compound VII comprises the following steps: adding a compound V into an organic solvent under the protection of nitrogen, adding alkali, cooling and stirring, adding a compound VI p-nitrophenyl chloroformate into the reaction solution, continuing to react at low temperature, and obtaining a compound VII after the detection reaction is finished, wherein the synthetic route is as follows:
Figure BDA0002420633450000032
preferably, the base is one or two selected from triethylamine, pyridine, potassium carbonate, N-methylmorpholine and N, N-diisopropylethylamine, and particularly preferably triethylamine.
Preferably, the organic solvent for reaction is selected from one or a mixture of dichloromethane, chloroform, tetrahydrofuran and acetonitrile, and dichloromethane is particularly preferred.
In a preferred scheme, the reaction temperature is-15 ℃ to 5 ℃.
In a preferred scheme, the feeding molar ratio of the reaction compound V, the compound VI and the base is as follows: 1: 1.0-2.0: 1.1-2.0, and particularly preferably 1:1.1: 1.2.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: and (4) carrying out suction filtration under reduced pressure, washing a filter cake with dichloromethane and water, and drying to obtain an intermediate VII.
Wherein the intermediate compound V is prepared as follows:
the preparation method of the compound V comprises the following steps: adding the compound IV into a mixed acid solvent, controlling the temperature and stirring to dissolve the solid, and continuously stirring until the reaction is finished to obtain an intermediate V, wherein the synthetic route is as follows:
Figure BDA0002420633450000033
preferably, the mixed acid solvent is selected from one or a combination of a concentrated hydrochloric acid glacial acetic acid mixed system, a sulfuric acid glacial acetic acid mixed system and a trifluoroacetic acid glacial acetic acid mixed system, and particularly preferably a concentrated sulfuric acid glacial acetic acid mixed system.
In a preferred scheme, the reaction temperature is 55-70 ℃.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling the reaction solution to room temperature, adding water, stirring and pulping, cooling to about 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V.
Wherein the intermediate compound IV is prepared as follows:
adding a compound II into a mixed solution of acid and an organic solvent, stirring and dissolving, adding methylhydrazine, reacting at room temperature, evaporating an organic phase after the reaction is finished, and adding a mixture of acid and alcohol until the reaction is finished to obtain a compound IV, wherein the synthetic route is as follows:
Figure BDA0002420633450000041
preferably, the acid may be one of glacial acetic acid, hydrochloric acid, concentrated sulfuric acid, or a combination thereof, wherein glacial acetic acid is particularly preferred.
Preferably, the organic solvent is selected from one or a combination of dichloromethane, trichloromethane, tetrahydrofuran and 1, 2-dichloroethane.
Preferably, the mixed system of the acid and the alcohol is one or a combination of a trifluoroacetic acid/methanol mixed system, a hydrochloric acid/methanol mixed system and a glacial acetic acid/methanol mixed system.
In a preferable embodiment, the volume ratio of the acid to the organic solvent is 1: 2.0-4.0, and particularly preferably 1: 3.0.
Preferably, the volume ratio of the acid to the alcohol in the mixed system of the acid and the alcohol is as follows: vAcid(s)：VAlcohol(s)＝1:3.0～4.0。
In a preferable embodiment, the feeding molar ratio of the compound II to the compound III is 1: 1.0-2.0, and particularly preferably 1: 1.2.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling in ice bath, filtering under reduced pressure, washing the filter cake with glacial methanol, concentrating the liquid phase and removing the organic solvent to obtain a compound IV. .
The application of the compound VII in preparing temozolomide.
The compound VII is used for preparing temozolomide, and the preparation method comprises the following steps: adding a compound VII into an organic solvent, and stirring at a controlled temperature to obtain temozolomide, wherein the synthetic route is as follows:
Figure BDA0002420633450000042
preferably, the organic solvent is selected from one or a combination of N, N-dimethylformamide, tetrahydrofuran, toluene and acetonitrile, and N, N-dimethylformamide is particularly preferred.
In a preferable scheme, the reaction temperature is 40-70 ℃.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling to about-15 ℃ after the reaction is finished, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and drying to obtain temozolomide
Compared with the prior art, the invention has the following technical effects:
1. the novel temozolomide intermediate compound VII is provided, the temozolomide can be prepared by one-step cyclization, no oxidative cyclization reagent is needed in cyclization reaction, no dimerization impurity is generated, the whole synthesis method is simple and convenient to operate, the reaction yield is high, and the purity of the obtained product is high;
2. the invention also provides a novel preparation method of temozolomide, the whole synthesis method is simple and convenient to operate, high in reaction yield, high in purity of the obtained product and suitable for industrial production.
In conclusion, the invention provides a novel method for preparing temozolomide, which avoids using dangerous chemical reagents, ensures that a synthesized intermediate does not generate dimeric impurities, has milder reaction, is economic and environment-friendly, has higher yield, and is suitable for industrial production.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
The structure of the novel compound obtained by the invention is confirmed:
structural characterization of Compound IV
Figure BDA0002420633450000051
High resolution mass spectrum of compound IV: ESI-MS: M/z 151.0700[ M + H ]]+；1H NMR(500MHz,CDCl3)δ8.00(s,1H),7.23(s,1H),3.18(s,3H)；13C-NMR(125MHz,CDCl3)δ148.96,128.70,114.69,69.03,34.58.
Structural characterization of Compound VII
Figure BDA0002420633450000061
High resolution mass spectrum of compound VII: ESI-MS: M/z 334.0904[ M + H ]]+；1H-NMR(500MHz，CDCl3)δ8.79(s,1H),8.26-8.19(m,2H),7.17-7.11(m,2H),6.78(s,2H),6.19(s,1H),3.15(s,3H)；13C-NMR(125MHz,CDCl3)δ164.14,163.87,151.31,146.20,138.40,136.80,131.10,125.26,121.88,34.58.
Preparation of Compound IV
Example 1
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 360mL of dichloromethane, stirring to dissolve the compound II, slowly dripping methylhydrazine (13.43g, 0.29mol) into the reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying dichloromethane, adding 240mL of methanol and 60mL of trifluoroacetic acid, and stirring to react. Cooling in ice bath, filtering under reduced pressure, washing the filter cake with glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 92.5 percent and the HPLC purity of 99.92 percent.
Example 2
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 240mL of trichloromethane, stirring for dissolving, slowly dripping methylhydrazine (11.06g, 0.24mol) into a reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying the trichloromethane, adding 200mL of methanol and 60mL of hydrochloric acid, and stirring for reacting. Reducing the temperature in an ice bath, filtering under reduced pressure, washing a filter cake by using glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 88.1 percent and the HPLC purity of 99.87 percent.
Example 3
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 300mL of tetrahydrofuran, stirring to dissolve the compound II, slowly dripping methylhydrazine (22.11g, 0.48mol) into the reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying the tetrahydrofuran, adding 180mL of methanol and 60mL of glacial acetic acid, and stirring to react. Cooling in ice bath, filtering under reduced pressure, washing filter cake with glacial methanol, concentrating and removing organic solvent to obtain compound IV with yield of 86.3% and HPLC purity of 99.79%.
Example 4 (methylhydrazine, outside upper limit)
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 480mL of 1, 2-dichloroethane, stirring to dissolve, slowly dripping methylhydrazine (24.32g, 0.53mol) into the reaction system, reacting at room temperature, detecting the reaction is finished, spin-drying 1, 2-dichloroethane, adding 200mL of methanol and 60mL of trifluoroacetic acid, and stirring to react. Reducing the temperature in an ice bath, filtering under reduced pressure, washing a filter cake by using glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 82.1 percent and the HPLC purity of 99.68 percent.
Preparation of Compound V
Example 5
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of concentrated hydrochloric acid and 25mL of glacial acetic acid, heating to 60-65 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 98.4% and the HPLC purity is 99.91%.
Example 6
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of concentrated sulfuric acid and 25mL of glacial acetic acid, heating to 55-60 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 96.4%, and the HPLC purity is 99.88%.
Example 7
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of trifluoroacetic acid and 25mL of glacial acetic acid, heating to 65-70 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 95.4%, and the HPLC purity is 99.84%.
Preparation of Compound VII
Example 8
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and triethylamine (18.21g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, filter cakes are washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 98.9 percent, and the HPLC purity is 99.88 percent.
Example 9
Adding the intermediate V (25.8g, 0.15mol), 600mL of trichloromethane and triethylamine (16.70g, 0.165mol) into a reaction bottle, introducing nitrogen for protection, cooling to-15 ℃, and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in chloroform was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 96.9 percent, and the HPLC purity is 99.83 percent.
Example 10
Adding the intermediate V (25.8g, 0.15mol), tetrahydrofuran 600mL and triethylamine (30.36g, 0.30mol) into a reaction bottle, introducing nitrogen for protection, cooling to 5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in tetrahydrofuran was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 94.5 percent, and the HPLC purity is 99.78 percent.
Example 11
Adding the intermediate V (25.8g, 0.15mol), acetonitrile 600mL and triethylamine (15.18g, 0.15mol) into a reaction bottle, introducing nitrogen for protection, cooling to 0 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in acetonitrile was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 90.5 percent, and the HPLC purity is 99.79 percent.
Example 12
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and triethylamine (33.40g, 0.33mol) into a reaction bottle, introducing nitrogen for protection, cooling to 0 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, and a filter cake is washed by dichloromethane and water and dried to obtain an intermediate II with yield of 88.2% and HPLC purity of 99.72%.
Example 13
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and pyridine (14.24g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (30.23g, 0.15mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 94.4 percent, and the HPLC purity is 99.82 percent.
Example 14
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and potassium carbonate (24.88g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (60.47g, 0.30mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the dropwise addition, the reaction was continued for 6 hours, and the reaction mixture was left at room temperature for 20 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 93.6 percent, and the HPLC purity is 99.78 percent.
Example 15
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and N, N-diisopropylethylamine (23.26g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (66.51g, 0.33mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the dropwise addition, the reaction was continued for 6 hours, and the reaction mixture was left at room temperature for 20 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 86.3 percent, and the HPLC purity is 99.70 percent.
Preparation of temozolomide
Example 16
Dissolving the intermediate VII (20g, 0.06mol) in 200mL of N, N-dimethylformamide, heating to 50 ℃, stirring at a constant temperature, reacting, cooling to-15 ℃ after detection reaction, performing vacuum filtration, washing a filter cake with glacial ethanol, and performing vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 98.6%, and the HPLC purity is 99.89%. One or a combination of toluene and acetonitrile, and N, N-dimethylformamide is particularly preferred
Example 17
Dissolving the intermediate VII (20g, 0.06mol) in 200mL tetrahydrofuran, heating to 40 ℃, stirring at constant temperature, reacting, cooling to-10 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 96.6%, and the HPLC purity is 99.82%.
Example 18
Dissolving the intermediate VII (20g, 0.06mol) in 200mL of toluene, heating to 70 ℃, stirring at constant temperature for reaction, cooling to-15 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 94.5%, and the HPLC purity is 99.79%.
Example 19
Dissolving the intermediate VII (20g, 0.06mol) in 200mL acetonitrile, heating to 35 ℃, stirring at constant temperature for reaction, cooling to-15 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 93.8%, and the HPLC purity is 99.77%.
Comparative examples
5-aminoimidazole-4-carboxamide (80g, 634.32mmol), dichloromethane (1920mL), and triethylamine (176.82mL, 1268.63mmol) were sequentially added to a 5L three-necked round-bottomed flask equipped with a thermometer, and the mixture was stirred at 25 ℃ for 10 minutes to lower the temperature of the reaction system to 0 ℃ or lower, after 10 minutes, 4-nitrophenylchloroformate (255.71g,1268.36mmol) dissolved in 1280mL dichloromethane was added dropwise, and after 4 hours of reaction at 0 ℃ or lower, the temperature was controlled at 25 ℃ for 18 hours. And (3) leaching the reaction solution by using a Buchner funnel, pulping and washing the obtained filter cake for 1 hour by using a mixed solution of 1000mL of dichloromethane and 200mL of water, leaching again, washing the filter cake by using dichloromethane, and airing at normal temperature to obtain a yellow solid product, wherein the yield is 80.6%, and the HPLC purity is 97.72%.
To a 50mL round bottom flask was added in sequence intermediate 2(30g,103.02mmol), solvent tetrahydrofuran 240mL, and after stirring for 10 minutes, 33% methylamine alcohol solution (12.6mL,103.02mmol) was added slowly and the temperature was controlled at 25 ℃ for 5 hours. And (3) carrying out suction filtration on the reaction solution by using a Buchner funnel, washing the obtained filter cake by using 300mL of diethyl ether and 200mL of acetone mixed solution (diethyl ether: acetone is 3:2), stirring and pulping for 1 hour, washing the suction filtration filter cake by using acetone, and airing to obtain a light yellow product, wherein the yield is 76.6%, and the HPLC purity is 97.75%.
A1L three-necked round-bottomed flask was taken, and lithium chloride monohydrate (373.03g,6175mmol), glacial acetic acid (29mL), and water (290mL) were added in this order. Stirred at room temperature for 30 minutes. Adding the intermediate 3(29g, 158.32mmol), stirring at normal temperature for 30 minutes, placing the reaction bottle in a cooling circulating pump, controlling the temperature below 0 ℃, cooling for 10 minutes, dropwise adding an aqueous solution of sodium nitrite (14.5g dissolved in 58ml of water), controlling the temperature within-10-5 ℃, stirring the reaction mixture liquid at 0-5 ℃ for one hour, adding I2(4.00g,15.8mmol), reacting at normal temperature for 2 hours, dissolving an aqueous solution of sodium thiosulfate (29g in 290ml of water), and stirring for 20 minutes to finish the reaction. Extracting with 5L of dichloromethane for 8-10 times each time, filtering the extract, performing rotary evaporation concentration to obtain a solution, concentrating to 100ml of a solvent, and performing suction filtration to obtain a finished product of temozolomide pink, wherein the yield is 80.6% and the HPLC purity is 97.82%.

Claims (9)

1. A temozolomide intermediate compound represented by formula VII:
Figure FDA0002420633440000011
2. the intermediate compound VII of claim 1, wherein the process of preparation comprises the steps of: adding a compound V into an organic solvent under the protection of nitrogen, adding alkali, cooling and stirring to dissolve a solid, adding a compound VI, namely p-nitrophenyl chloroformate into a reaction solution, continuing to react at a low temperature, and obtaining a compound VII after the detection reaction is finished, wherein the reaction route is as follows:
Figure FDA0002420633440000012
3. the preparation method according to claim 2, wherein the base is selected from one or a combination of triethylamine, pyridine, potassium carbonate, N-methylmorpholine, N-diisopropylethylamine.
4. The preparation method according to claim 2, wherein the compound V, the compound VI and the base are fed in a molar ratio of: 1: 1.0-2.0: 1.1-2.0.
5. The preparation method according to claim 2, wherein the organic solvent is selected from one or a combination of dichloromethane, chloroform, tetrahydrofuran and acetonitrile; the reaction temperature is-15 ℃ to 5 ℃.
6. Use of compound v II according to claim 1 for the preparation of temozolomide.
7. A process for preparing temozolomide from compound VII of claim 1, comprising the steps of: adding a compound VII into an organic solvent, and stirring at a controlled temperature to obtain temozolomide, wherein the synthetic route is as follows:
Figure FDA0002420633440000013
8. the preparation method according to claim 7, wherein the organic solvent is selected from one or a combination of N, N-dimethylformamide, tetrahydrofuran, toluene and acetonitrile.
9. The method according to claim 7, wherein the reaction temperature is 40 to 70 ℃.
CN202010205396.9A 2020-03-22 2020-03-22 Temozolomide intermediate compound VII Active CN113493417B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010205396.9A CN113493417B (en) 2020-03-22 2020-03-22 Temozolomide intermediate compound VII

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010205396.9A CN113493417B (en) 2020-03-22 2020-03-22 Temozolomide intermediate compound VII

Publications (2)

Publication Number Publication Date
CN113493417A true CN113493417A (en) 2021-10-12
CN113493417B CN113493417B (en) 2024-03-15

Family

ID=77993845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010205396.9A Active CN113493417B (en) 2020-03-22 2020-03-22 Temozolomide intermediate compound VII

Country Status (1)

Country Link
CN (1) CN113493417B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659789A (en) * 2011-04-27 2012-09-12 四川科瑞德凯华制药有限公司 Method preparing temozolomide in one-pot mode and refining method of temozolomide
CN103626772A (en) * 2012-08-24 2014-03-12 国药一心制药有限公司 Synthetic method for temozolomide and intermediate
CN109467534A (en) * 2017-09-07 2019-03-15 湖北半天制药有限公司 A kind of synthetic method of Temozolomide intermediate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659789A (en) * 2011-04-27 2012-09-12 四川科瑞德凯华制药有限公司 Method preparing temozolomide in one-pot mode and refining method of temozolomide
CN103626772A (en) * 2012-08-24 2014-03-12 国药一心制药有限公司 Synthetic method for temozolomide and intermediate
CN109467534A (en) * 2017-09-07 2019-03-15 湖北半天制药有限公司 A kind of synthetic method of Temozolomide intermediate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAVIN D. BROWN，等: "Antitumor Imidazotetrazines. 40.1 Radiosyntheses of [4-11C-Carbonyl]- and [3-N-11C-Methyl]-8-carbamoyl-3-methylimidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (Temozolomide) for Positron Emission Tomography (PET) Studies", 《J. MED. CHEM.》, vol. 45, pages 5448 - 5457, XP002637804, DOI: 10.1021/jm020921f *
MARTIN J. WANNER，等: "A new synthesis of temozolomide", 《J. CHEM. SOC., PERKIN TRANS. 1》, pages 1877 - 1880 *
YONGFENG WANG，等: "Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide", 《J. ORG. CHEM.》, vol. 62, pages 7288 - 7294 *

Also Published As

Publication number Publication date
CN113493417B (en) 2024-03-15

Similar Documents

Publication Publication Date Title
CN106496187A (en) A kind of synthetic method for preparing PARP inhibitor Niraparib
CN110183445B (en) Synthetic method of moxifloxacin and derivatives thereof
CN102351778A (en) Preparation method of arbidol hydrochloride
CN109384827A (en) A kind of budesonide industrialized process for preparing
EP3527556B1 (en) Method for preparing deuterated imidazole diketone compound
CN110655517A (en) Preparation method of doriravir open-loop impurities and impurities thereof
CN114805327A (en) Intermediate for thiohydantoin medicine and preparation method and application thereof
CN112010913B (en) Preparation method of 4-deoxy daunorubicin
EP3692030B1 (en) Process for the preparation of ridinilazole using acid addition salts
CN113493417A (en) Temozolomide intermediate compound VII
CN113493418A (en) Temozolomide intermediate compound IV
CN113493458A (en) Preparation method of temozolomide
CN115215820A (en) Preparation method of cabazitaxel impurity F
CN111574520B (en) Riagliptin intermediate compound V
CN111574463B (en) Rivastigmine intermediate compound IV
CN113372375B (en) Preparation method of temsirolimus intermediate
CN111675653A (en) Preparation method and application of impurities of 4-aminoquinoline compound
CN110563721A (en) Preparation method of azasetron hydrochloride
CN114539288B (en) Preparation method of everolimus
CN107216360B (en) A method of preparing rope Citropten
CN114560845B (en) Crystal form alpha of quinoline compound, and preparation method and application thereof
CN104098524A (en) 1-m-methoxy benzoyl-3-phenyl-1, 4-dihydro-1,2,4,5-tetrazine and preparation and application thereof
CN110684000B (en) Process for preparing benzofuran derivatives
WO2024022483A1 (en) A bifunctional pharmaceutical intermediate and its preparation method and use
CN114805360A (en) Preparation method of temozolomide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant